SCHEMBL31269020

SCHEMBL31269020

CC1(Oc2ncnc3c2nc(-c2ccc(CCCCC(=O)O)cc2Cl)n3Cc2cccc(Cl)c2)CC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FFAR4 Q5NUL3 3/20 0.38
▸ FFAR1 O14842 1/20 0.38
▸ PTGDR2 Q9Y5Y4 1/20 0.37
▸ CNR1 P21554 1/20 0.36
▸ PDE10A Q9Y233 1/20 0.34
▸ NAAA Q02083 2/20 0.34
▸ PIK3CD O00329 2/20 0.34
▸ THRA P10827 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ SCN1A P35498 1/20 0.33
▸ SCN8A Q9UQD0 1/20 0.33
▸ SLC22A12 Q96S37 1/20 0.33
▸ TLR7 Q9NYK1 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HTR6 P50406 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.32
▸ CHRM2 P08172 1/20 0.32
▸ CHRM3 P20309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983451 0.91 PLA2G2A (0.38) PTGDR2CNR1PIK3CDSCN1ASCN8A
SCHEMBL31268872 0.90 PLA2G2A (0.37) PTGDR2CNR1PIK3CDSCN1ASCN8A
SCHEMBL31269373 0.90 PLA2G2A (0.37) PTGDR2CNR1PIK3CDSCN1ASCN8A
SCHEMBL30983523 0.90 PLA2G2A (0.38) FFAR4PTGDR2CNR1PIK3CDTLR7
SCHEMBL31268871 0.90 TLR7 (0.34) FFAR4FFAR1PTGDR2CNR1SCN1A
SCHEMBL31268939 0.89 CNR1 (0.35) FFAR4FFAR1PTGDR2CNR1PDE10A
SCHEMBL31269372 0.88 CNR1 (0.35) FFAR4FFAR1PTGDR2CNR1PDE10A
SCHEMBL31269035 0.88 CNR1 (0.36) FFAR4FFAR1PTGDR2CNR1PIK3CD
SCHEMBL31269133 0.87 PLA2G2A (0.38) PTGDR2CNR1PDE10APIK3CDSCN1A
SCHEMBL31268855 0.86 CNR1 (0.38) PTGDR2CNR1PIK3CDSCN1ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback